Upbeat earnings lifted the market during the midday with the Dow rising 7 points to 15,283. Nasdaq rose 6 points to 3477.
On the upside
Eagle Bulk Shipping (Nasdaq: EGLE) reversed year ago losses to post a profit for the first quarter as revenue climbed.
Shares of National Bank of Greece (NYSE: NBG) climbed for the fourth day in a row despite a lack of news.
Halozyme Therapeutics (Nasdaq: HALO) expects to present positive data from a Phase 1b study of its pancreatic cancer treatment PEGPH20 at the 2013 American Society of Clinical Oncology Annual Meeting.
On the downside
Infinity Pharmaceuticals (Nasdaq: INFI) will present clinical trial data for its IPI-145 at two upcoming conferences.
Oncothyreon (Nasdaq: ONTY) reported disappointing results from a Phase III START trial of its lung cancer treatment L-BLP25.
Cyclacel Pharmaceuticals (Nasdaq: CYCC) priced its public offering of approximately 6.67 million common shares at the discounted price of $3.00 per share.
In the broad market, declining issues outpaced advancers by a margin of more than 10 to 9 on the NYSE and by nearly 10 to 9 on Nasdaq. The broader S&P 500 index eased a point to 1657.
